Esperion Therapeutis.Inc. buy Global_Player
Summary
This prediction ended on 11.12.22 with a price of €4.76. The price of Esperion Therapeutis.Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -26.62%. Global_Player has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | 4.605% | 4.605% | 46.419% | 56.235% |
| iShares Core DAX® | -2.117% | -7.974% | -1.733% | 53.340% |
| iShares Nasdaq 100 | -1.323% | -0.066% | 16.602% | 81.164% |
| iShares Nikkei 225® | -0.324% | -6.382% | 25.629% | 52.301% |
| iShares S&P 500 | -1.568% | -1.965% | 10.831% | 60.913% |
According to Global_Player what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Cons
Comments by Global_Player for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Global_Player for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
29.08.25
29.08.26
15.09.25
Esperion Therapeutis.Inc.
26.02.25
26.02.26
01.03.25
Esperion Therapeutis.Inc.
25.04.24
25.04.25
27.04.24
Esperion Therapeutis.Inc.
28.08.23
28.08.24
30.08.23
Esperion Therapeutis.Inc.
26.07.21
26.07.22
08.08.21


